Diagnostic Value of Retinol-binding Protein 4 in Diabetic Nephropathy: a Systematic Review and Meta-analysis

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 May 7

PMID 38711978

Authors

Xiaodan Cao

Guanghui Zhong

Tinglong Jin

Weijiao Hu

Jin Wang

Bo Shi

Renxiong Wei

Affiliations

Soon will be listed here.

Abstract

Objective: Diabetic nephropathy (DN) is a major microvascular complication of diabetes and the leading cause of end-stage renal disease. Early detection and prevention of DN are important. Retinol-binding protein 4 (RBP4) has been considered as a single diagnostic marker for the detection of renal impairment. However, the results have been inconsistent. The present meta-analysis aimed to determine the diagnostic potential of RBP4 in patients in type 2 diabetes mellitus (T2DM) with DN.

Methods: We searched PubMed, Web of Science, Embase, Wanfang and CNKI databases from inception until January 2024. The meta-analysis was performed by Stata version 15.0, and sensitivity, specificity, positive and negative likelihood ratios (PLR and NLR), diagnostic odds ratio (DOR) and area under the curve (AUC) were pooled. The Quality Assessment of Diagnostic Accuracy Studies-2 tool was utilized to assess the quality of each included study. In addition, heterogeneity and publication bias were evaluated.

Results: Twenty-nine studies were included in the meta-analysis. The pooled sensitivity and specificity were 0.76 [95% confidence interval (CI), 0.71-0.80] and 0.81 (95% CI, 0.76-0.85), respectively. The results showed a pooled PLR of 4.06 (95% CI, 3.16-5.21), NLR of 0.29 (95% CI, 0.24-0.36) and DOR of 13.76 (95% CI, 9.29-20.37). The area under the summarized receiver operating characteristic curve was given a value of 0.85 (95% CI, 0.82-0.88). No obvious publication bias existed in the Deeks' funnel plot asymmetry test.

Conclusion: Our findings suggest that RBP4 has a promising diagnostic value with good sensitivity and specificity for patients with T2DM with DN.

Citing Articles

PTHrP Promotes RBP4 Expression Under the Control of PPARγ in the Kidney.

Nieto-Bona M, Carrasco A, Medina-Gomez G, Bosch R, Izquierdo-Lahuerta A Int J Mol Sci. 2025; 26(1.

PMID: 39795999 PMC: 11719952. DOI: 10.3390/ijms26010142.

References

Olsen T, Blomhoff R . Retinol, Retinoic Acid, and Retinol-Binding Protein 4 are Differentially Associated with Cardiovascular Disease, Type 2 Diabetes, and Obesity: An Overview of Human Studies. Adv Nutr. 2019; 11(3):644-666. PMC: 7231588. DOI: 10.1093/advances/nmz131. View

Yao-Borengasser A, Varma V, Bodles A, Rasouli N, Phanavanh B, Lee M . Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab. 2007; 92(7):2590-7. PMC: 2893415. DOI: 10.1210/jc.2006-0816. View

Yang J, Liu Z . Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy. Front Endocrinol (Lausanne). 2022; 13:816400. PMC: 9174994. DOI: 10.3389/fendo.2022.816400. View

Abbasi F, Moosaie F, Khaloo P, Dehghani Firouzabadi F, Fatemi Abhari S, Atainia B . Neutrophil Gelatinase-Associated Lipocalin and Retinol-Binding Protein-4 as Biomarkers for Diabetic Kidney Disease. Kidney Blood Press Res. 2020; 45(2):222-232. DOI: 10.1159/000505155. View

Xu M, Li X, Wang J, Wang X, Huang Y, Cheng Q . Retinol-binding protein 4 is associated with impaired glucose regulation and microalbuminuria in a Chinese population. Diabetologia. 2009; 52(8):1511-9. DOI: 10.1007/s00125-009-1386-8. View

Lin Z, Dai S, Zhao J, Jiang Y . Application of urinary N-acetyl-β-D-glucosaminidase combined with serum retinol-binding protein in early detection of diabetic nephropathy. World J Diabetes. 2023; 14(6):883-891. PMC: 10294068. DOI: 10.4239/wjd.v14.i6.883. View

Cabre A, Lazaro I, Girona J, Manzanares J, Marimon F, Plana N . Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. J Intern Med. 2007; 262(4):496-503. DOI: 10.1111/j.1365-2796.2007.01849.x. View

Yang Q, Graham T, Mody N, Preitner F, Peroni O, Zabolotny J . Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005; 436(7049):356-62. DOI: 10.1038/nature03711. View

Samsu N . Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. Biomed Res Int. 2021; 2021:1497449. PMC: 8285185. DOI: 10.1155/2021/1497449. View

10.

Mahfouz M, Assiri A, Mukhtar M . Assessment of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Retinol-Binding Protein 4 (RBP4) in Type 2 Diabetic Patients with Nephropathy. Biomark Insights. 2016; 11:31-40. PMC: 4756860. DOI: 10.4137/BMI.S33191. View

11.

Selby N, Taal M . An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020; 22 Suppl 1:3-15. DOI: 10.1111/dom.14007. View

12.

Graham T, Yang Q, Bluher M, Hammarstedt A, Ciaraldi T, Henry R . Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006; 354(24):2552-63. DOI: 10.1056/NEJMoa054862. View

13.

Perumalsamy S, Wan Ahmad W, Huri H . Retinol-Binding Protein-4-A Predictor of Insulin Resistance and the Severity of Coronary Artery Disease in Type 2 Diabetes Patients with Coronary Artery Disease. Biology (Basel). 2021; 10(9). PMC: 8468650. DOI: 10.3390/biology10090858. View

14.

Flores-Cortez Y, Barragan-Bonilla M, Mendoza-Bello J, Gonzalez-Calixto C, Flores-Alfaro E, Espinoza-Rojo M . Interplay of retinol binding protein 4 with obesity and associated chronic alterations (Review). Mol Med Rep. 2022; 26(1). PMC: 9185696. DOI: 10.3892/mmr.2022.12760. View

15.

Chang Y, Lin K, Wang C, Hsieh M, Hsiao P, Shin S . Elevated serum retinol-binding protein 4 concentrations are associated with renal dysfunction and uric acid in type 2 diabetic patients. Diabetes Metab Res Rev. 2008; 24(8):629-34. DOI: 10.1002/dmrr.894. View

16.

Murata M, Saito T, Otani T, Sasaki M, Ikoma A, Toyoshima H . An increase in serum retinol-binding protein 4 in the type 2 diabetic subjects with nephropathy. Endocr J. 2009; 56(2):287-94. DOI: 10.1507/endocrj.k08e-242. View

17.

Blaner W . Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders. Pharmacol Ther. 2019; 197:153-178. PMC: 6520171. DOI: 10.1016/j.pharmthera.2019.01.006. View

18.

Marino M, Andrews D, Brown D, McCluskey R . Transcytosis of retinol-binding protein across renal proximal tubule cells after megalin (gp 330)-mediated endocytosis. J Am Soc Nephrol. 2001; 12(4):637-648. DOI: 10.1681/ASN.V124637. View

19.

Schiborn C, Weber D, Grune T, Biemann R, Jager S, Neu N . Retinol and Retinol Binding Protein 4 Levels and Cardiometabolic Disease Risk. Circ Res. 2022; 131(7):637-649. PMC: 9473720. DOI: 10.1161/CIRCRESAHA.122.321295. View

20.

Toruner F, Altinova A, Akturk M, Kaya M, Arslan E, Bukan N . The relationship between adipocyte fatty acid binding protein-4, retinol binding protein-4 levels and early diabetic nephropathy in patients with type 2 diabetes. Diabetes Res Clin Pract. 2010; 91(2):203-7. DOI: 10.1016/j.diabres.2010.11.011. View